Status:
COMPLETED
Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Interstitial Lung Disease
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Eligibility:
All Genders
18-85 years
Brief Summary
The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the differenc...
Detailed Description
ILD patients with serum ANCA-positivity were enrolled in this study. 1. Baseline data collection: 1. Demographics information (age, gender) 2. Clinical course 3. Clinical symptoms and signs...
Eligibility Criteria
Inclusion
- Males and females
- Aged from 18 to 85 years with informed consent
- Have a diagnosis of ILD based on clinical symptoms and radiologic features, with or without histopathologic results
- Have available ANCA testing results during the first visit and follow-up period
Exclusion
- Connective tissue disease associated ILD
- ILD induced by drug, environment, or occupational exposure
- Hypersensitivity pneumonitis and sarcoidosis
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04413149
Start Date
April 1 2014
End Date
April 1 2020
Last Update
May 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730